Clinical trialNANot yet recruiting
PET Imaging of 68Ga-NOTA-H006 in Malignancy
A Study to Evaluate 5T4 Expression in Malignant Tumors Using 68Ga-NOTA-H006
- Outcome
- Ongoing
- Phase
- NA
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- December 2023
- Expected end
- December 2028
- Enrollment
- 15 participants
- Sites
- 1
- Primary outcomes
- Establishment and optimization of imaging method for 68Ga-NOTA-H006 PET
- Sponsor
- Other
- Results posted
- No
- Last update
- 8 December 2023
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
5T4, also known as trophoblast glycoprotein, is an oncofoetal antigen expressing in fetal development and cancer but rarely in adult. The high expression of 5T4 in malignancy was found be associated with poor clinical outcomes in ovarian, gastric and colorectal cancers. Several antibody drug conjugates are currently under development for cancer therapy in preclinic and clinic stages. Previously, investigators engineered a 5T4-specific biomolecule with nanomolar binding affinity. Radiolabeling with gallium-68 resulted in 68Ga-NOTA-H006 which showed 5T4 expression in a variety of xenograft models. Thus, the aims of current study are to evaluate the distribution and dosimetry of this novel tracer, and to explore the diagnostic values of 68Ga-NOTA-H006 in malignant tumors.